DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

This article was originally published here

Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts. A non-invasive, once-daily, epicutaneous

The post DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply